الفهرس 
Non-Alcoholic Fatty Liver DiseaseOnly 14 pages are availabe for public view
 |  | from | 152 |  |  |
| | | from | 152 | | |
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of conditions, ranging from a simple fatty liver to non-alcoholic steatohepatitis (NASH) with or without fibrosis, to cirrhosis and its complications.
Liver biopsy is currently considered the gold standard for diagnosing NAFLD and fibrosis. Non-invasive liver fibrosis tests have been extensively developed recently and offer other alternatives for staging fibrosis
Aims: To compare between different non-invasive methods for diagnosis of non- alcoholic fatty liver disease.
Methodology: This was a cohort study conducted from the period between September 1, 2015 to June 30, 2016.100 patients (age range of 20-70 years) with fatty liver disease on abdominal ultrasonography finding were selected from Hepatology and Gastroenterology clinics, Ain shams university hospitals and El- sahel Teaching Hospital for treatment and research (All ethical guidelines for research were followed and informed consent was obtained from all patients before the procedures).
Results: group I: 50 diabetic patients with non-alcoholic fatty liver disease (mainly type 2). group II: 50 non-diabetic patients with non-alcoholic fatty liver disease.
Conclusion: Our study had shown that the combination of Fibroscan, Fib-4 and NAFLD fibrosis score provides a valuable non-invasive method in assessment of severity of NAFLD patients, and this can eliminate the need for liver biopsy in patients without clear indication.
Recommendations: In view of the frequency of non-alcoholic fatty liver disease, all individuals with steatosis should be screened for metabolic risk factors (obesity, dyslipidemia, hypertension, impaired glucose tolerance /diabetes) by liver enzymes and /or ultrasound as a part of routine work-up.